Effect of (E)-5-(2-Bromovinyl)-2′-deoxyuridine on replication of Epstein-Barr Virus in human lymphoblastoid cell lines

Lin, Jung‐Chung; Smith, Marilyn S.; Choi, Etsuyo I.; Clercq, Erik De; Verbruggen, Alfons; Pagano, Joseph S.

doi:10.1016/s0166-3542(85)80018-8

Cited by 10 publications

(8 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is not in accordance with previously published results by Lin et al [41,42] and Pagano [43]. These authors found BVDU to be a potent and selective inhibitor of EBV replication using the virus-producing P3HR-1 cells (EC 50 = 0.06 M) and superinfected Raji cells [41][42][43]. Methodological differences between slot-blot hybridisation and cRNA-DNA hybridisation cannot explain these divergent findings.…”

Section: Discussioncontrasting

confidence: 66%

Antiviral activity of cyclosaligenyl prodrugs of the nucleoside analogue bromovinyldeoxyuridine against herpes viruses

Meerbach

Meier

Sauerbrei

et al. 2006

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 66%

Antiviral activity of cyclosaligenyl prodrugs of the nucleoside analogue bromovinyldeoxyuridine against herpes viruses

Meerbach

Meier

Sauerbrei

et al. 2006

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

“…Compounds that inhibit replication of EBV in vitro include adenine arabinoside (3,11), phosphonoformic acid, and phosphonoacetate (16,60,63,77), a class of halogenated nucleoside analogs exemplified by FIAC [1-(2-fluoro-2-deoxy-␤-D-arabinofuranosyl)-5-iodocytosine] (42,46), BVDU [E-5-(2-bromovinyl)-2Ј-deoxyuridine) (43,44), ganciclovir (39), acyclovir (ACV) (12,24,45), and the phosphonated nucleoside analogs HPMPC {(S)-1-[(3-hydroxy-2-phosphonylmethoxy)propyl]cytosine} and related compounds (40,41). Nucleoside analogs and the pyrophosphate analogs phosphonoformic acid and phosphonoacetate inhibit replication of most or all of the herpesviruses.…”

mentioning

confidence: 99%

Inhibition of Epstein-Barr Virus Replication by a Benzimidazole l -Riboside: Novel Antiviral Mechanism of 5,6-Dichloro-2-(Isopropylamino)-1-β- l -Ribofuranosyl-1H-Benzimidazole

Zacny

Gershburg

Davis

et al. 1999

J Virol

View full text Add to dashboard Cite

Although a number of antiviral drugs inhibit replication of Epstein-Barr virus (EBV) in cell culture, and acyclovir (ACV) suppresses replication in vivo, currently available drugs have not proven effective for treatment of EBV-associated diseases other than oral hairy leukoplakia. Benzimidazole riboside compounds represent a new class of antiviral compounds that are potent inhibitors of human cytomegalovirus (HCMV) replication but not of other herpesviruses. Here we characterize the effects of two compounds in this class against lytic replication of EBV induced in a Burkitt lymphoma cell line latently infected with EBV. We analyzed linear forms of EBV genomes, indicative of lytic replication, and episomal forms present in latently infected cells by terminal probe analysis followed by Southern blot hybridization as well as the high-molecular-weight unprocessed viral DNA by pulsed-field gel electrophoresis. d-Ribofuranosyl benzimidazole compounds that act as inhibitors of HCMV DNA maturation, including BDCRB (5,6-dichloro-2-bromo-1-β-d-ribofuranosyl-1H-benzimidazole), did not affect the accumulation of high-molecular-weight or monomeric forms of EBV DNA in the induced cells. In contrast, the generation of linear EBV DNA as well as precursor viral DNA was sensitive to thel-riboside 1263W94 [5,6-dichloro-2-(isopropylamino)-1-β-l-ribofuranosyl-1H-benzimidazole]. The 50% inhibitory concentration range for 1263W94 was 0.15 to 1.1 μM, compared with 10 μM for ACV. Thus, 1263W94 is a potent inhibitor of EBV. In addition, 1263W94 inhibited the phosphorylation and the accumulation of the essential EBV replicative cofactor, early antigen D.

show abstract

“…The combination of acyclovir and AZT, while it is not synergistic, has an additive effect against EBV replication. AZT may prove to be a useful drug for treatment of coinfections with human immunodeficiency virus and EBV.In recent years, we have shown that several nucleoside analogs selectively inhibit the replication of Epstein-Barr virus (EBV) (14)(15)(16)(17). One drug has been tested in trials in patients with infectious mononucleosis (6, 21; C. M. Van der …”

mentioning

confidence: 99%

mentioning

confidence: 99%

“…In recent years, we have shown that several nucleoside analogs selectively inhibit the replication of Epstein-Barr virus (EBV) (14)(15)(16)(17). One drug has been tested in trials in patients with infectious mononucleosis (6, 21; C. M. Van der Horst, J. Joncas, G. Ahronheim, G. Stein, M. Gurwith, G. Fleisher, J. L. Sullivan, J. Sixbey, C. Sumaya, R. Schooley, S. Roland Sweezy, and J. S. Pagano, Program Abstr.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Anti-human immunodeficiency virus agent 3'-azido-3'-deoxythymidine inhibits replication of Epstein-Barr virus

Lin

Zhang

Smith

et al. 1988

Antimicrob Agents Chemother

View full text Add to dashboard Cite

We show that the anti-human immunodeficiency virus agent, 3'-azido-3'-deoxythymidine (AZT), which suppresses infectivity and cytopathic effects of human immunodeficiency virus, also effectively inhibits Epstein-Barr virus (EBV) DNA replication. However, AZT has no effect on four other human herpesviruses: cytomegalovirus, varicella-zoster virus, and herpes simplex virus types 1 and 2. The combination of acyclovir and AZT, while it is not synergistic, has an additive effect against EBV replication. AZT may prove to be a useful drug for treatment of coinfections with human immunodeficiency virus and EBV.In recent years, we have shown that several nucleoside analogs selectively inhibit the replication of Epstein-Barr virus (EBV) (14)(15)(16)(17). One drug has been tested in trials in patients with infectious mononucleosis (6, 21; C. M. Van der

show abstract

Effect of (E)-5-(2-Bromovinyl)-2′-deoxyuridine on replication of Epstein-Barr Virus in human lymphoblastoid cell lines

Cited by 10 publications

References 8 publications

Antiviral activity of cyclosaligenyl prodrugs of the nucleoside analogue bromovinyldeoxyuridine against herpes viruses

Antiviral activity of cyclosaligenyl prodrugs of the nucleoside analogue bromovinyldeoxyuridine against herpes viruses

Inhibition of Epstein-Barr Virus Replication by a Benzimidazole l -Riboside: Novel Antiviral Mechanism of 5,6-Dichloro-2-(Isopropylamino)-1-β- l -Ribofuranosyl-1H-Benzimidazole

Anti-human immunodeficiency virus agent 3'-azido-3'-deoxythymidine inhibits replication of Epstein-Barr virus

Contact Info

Product

Resources

About